http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen
-
Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection
-
Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection
-
Cathie Wood's ARK Adds ~1.7M Shares of Twitter (TWTR), Sells Apple (AAPL), Alibaba (BABA)
-
Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio
-
Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio
-
Adaptive Biotechnologies (ADPT) Launches T-Detect COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection
-
Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection
-
Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection
-
Adaptive Biotechnologies (ADPT) to Collaborate with AstraZeneca (AZN) in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
-
Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
-
Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
-
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
-
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
-
Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
-
Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
-
Adaptive Biotechnologies (ADPT) Announces Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections
-
Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections
-
Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections
-
Adaptive Biotechnologies (ADPT) Enters Collaboration with GSK for clonoSEQ Assay
-
Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio
-
Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio
-
Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit
-
Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit
-
Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia
-
Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia
-
Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2
-
Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease
-
Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease
-
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020
-
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020
-
Adaptive Biotechnologies and Microsoft launch groundbreaking ImmuneCODE database to share populationwide immune response to the COVID-19 virus
-
UPDATE – Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
-
UPDATE – Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
-
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
-
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
-
Adaptive Biotechnologies to Present at the BofA Securities 2020 Healthcare Conference
-
Adaptive Biotechnologies to Present at the BofA Securities 2020 Healthcare Conference
-
Adaptive Biotechnologies (ADPT), Microsoft (MSFT) Launch Virtual ImmuneRACE Study on COVID-19
-
Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing
-
Adaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020
-
Adaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020
-
Amgen And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration
-
Amgen (AMGN), Adaptive Biotechnologies (ADPT) Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
-
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
-
Divide & Conquer, Developing New Class of Cancer Therapeutics to Disrupt Cell-to-Cell Communication, Emerges from Stealth as New Paper by Co-Founder is Published in Nature
-
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) to Ring The Nasdaq Stock Market Opening Bell
-
INVESTOR ALERT: Goldberg Law PC Announces an Ongoing Investigation of Claims against Adeptus Health Inc. and Encourages Shareholders to Contact the Firm
-
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces an Ongoing Investigation of Claims against Adeptus Health Inc. and Encourages Shareholders to Contact the Firm
-
Ochsner Health System and Adeptus Health Partner to Enhance Emergency Medical Care in Louisiana

